Triose‐phosphate isomerase is a novel target of miR‐22 and miR‐28, with implications in tumorigenesis

Aerobic glycolysis is the hallmark of many cancer cells that results in a high rate of adenosine triphosphate (ATP) production and, more importantly, biosynthetic intermediates, which are required by the fast‐growing tumor cells. The molecular mechanism responsible for the increased glycolytic influx of tumor cells is still not fully understood. In the present study, we have attempted to address the above question by exploring the role of the glycolytic enzyme, triose‐phosphate isomerase (TPI), in the cancer cells. The western blot analysis of the 30 human colorectal cancer samples depicted higher post‐transcriptional expression of TPI in the tumor tissue relative to the normal tissue. In addition, we identified two novel microRNAs, miR‐22 and miR‐28, that target the TPI messenger RNA (mRNA) and regulate its expression. miR‐22 and the miR‐28 showed significant inverse expression status viz‐a‐viz the expression of the TPI. The specificity of the miR‐22/28 regulation of the TPI mRNA was confirmed by various biochemical and mutagenic assays. Moreover, the hypoxia conditions resulted in an increased expression of the TPI protein, with a concomitant decrease in miR‐22/28. The physiological significance of the TPI and miR‐22/28 interaction for the glycolytic influx was confirmed by the l‐lactate production in the HCT‐116+/+ cells. Overall, our data demonstrate the novel microRNA mediated post‐transcriptional regulation of the TPI glycolytic enzyme, which may be one of the possible reasons for the increased glycolytic capacity of the tumor cells.

[1]  P. Sears triosephosphate isomerase , 2020, Catalysis from A to Z.

[2]  A. Mighell Proliferating Cell Nuclear Antigen , 2020, Definitions.

[3]  P. Ouyang,et al.  Clinical significance and prognostic value of Triosephosphate isomerase expression in gastric cancer , 2017, Medicine.

[4]  A. Ramiro,et al.  miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. , 2017, Blood.

[5]  Shuai Jiang,et al.  MicroRNA regulation and analytical methods in cancer cell metabolism , 2017, Cellular and Molecular Life Sciences.

[6]  Yan Lin,et al.  The inhibition role of miR-22 in hepatocellular carcinoma cell migration and invasion via targeting CD147 , 2017, Cancer Cell International.

[7]  Jingqiu Li,et al.  PFKL/miR-128 axis regulates glycolysis by inhibiting AKT phosphorylation and predicts poor survival in lung cancer. , 2016, American journal of cancer research.

[8]  D. He,et al.  Down-Regulated Mir-22 as Predictive Biomarkers for Prognosis ofCervical Cancer , 2015 .

[9]  W. Xu,et al.  miR-22 is down-regulated in esophageal squamous cell carcinoma and inhibits cell migration and invasion , 2014, Cancer Cell International.

[10]  Xuemei Wang,et al.  Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer , 2014, Diagnostic Pathology.

[11]  Y. Tu,et al.  Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis , 2013, Diagnostic Pathology.

[12]  M. Hussain Micro-RNAs (miRNAs): genomic organisation, biogenesis and mode of action , 2012, Cell and Tissue Research.

[13]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[14]  Hoyun Lee,et al.  Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer , 2010, FEBS letters.

[15]  J. Vandesompele,et al.  MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer , 2010, BMC Cancer.

[16]  Russell G. Jones,et al.  Tumor suppressors and cell metabolism: a recipe for cancer growth. , 2009, Genes & development.

[17]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[18]  Hoyun Lee,et al.  Characterization of proliferating cell nuclear antigen (PCNA) isoforms in normal and cancer cells: There is no cancer‐associated form of PCNA , 2007, FEBS letters.

[19]  P. Vaupel,et al.  Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.

[20]  Wenwen Wu,et al.  Protein Pattern Difference in the Colon Cancer Cell Lines Examined by Two-Dimensional Differential In-Gel Electrophoresis and Mass Spectrometry , 2006, Surgery Today.

[21]  Judit Ovádi,et al.  Triosephosphate isomerase deficiency: Facts and doubts , 2006, IUBMB life.

[22]  Ken Garber,et al.  Energy Deregulation: Licensing Tumors to Grow , 2006, Science.

[23]  K. Livak,et al.  Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.

[24]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[25]  K. Greulich,et al.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. , 2004, Genomics.

[26]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[27]  Qing‐Yu He,et al.  Proteomics of buccal squamous cell carcinoma: The involvement of multiple pathways in tumorigenesis , 2004, Proteomics.

[28]  T. Tsuruo,et al.  Hypoxic up-regulation of triosephosphate isomerase expression in mouse brain capillary endothelial cells. , 2004, Archives of biochemistry and biophysics.

[29]  A. Kurtz,et al.  Hypoxia up-regulates triosephosphate isomerase expression via a HIF-dependent pathway , 2004, Pflügers Archiv.

[30]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[31]  B. Seliger,et al.  Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. , 2003, Biochimica et biophysica acta.

[32]  G. Auer,et al.  Polypeptide Expression in Prostate Hyperplasia and Prostate Adenocarcinoma , 2000, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[33]  C. Bennett,et al.  The 28K protein in urinary bladder, squamous metaplasia and urine is triosephosphate isomerase. , 1997, Clinical biochemistry.

[34]  T. Tsuruo,et al.  Identification of genes differentially expressed in B16 murine melanoma sublines with different metastatic potentials. , 1996, Cancer research.

[35]  M. Schwartz,et al.  Enzymes in cancer. , 1989, Clinics in laboratory medicine.

[36]  D W Banner,et al.  On the three-dimensional structure and catalytic mechanism of triose phosphate isomerase. , 1981, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[37]  F. Lagae,et al.  Enzymes in cancer. III. Triosephosphate isomerase activity of human blood serum in normal individuals and in individuals with various pathological conditions , 1961, Cancer.

[38]  Kurihara,et al.  Three-dimensional Structure , 2006 .

[39]  B. F. Gurney ENZYMES. I. , 1965, Oral hygiene.